Communiqués Clinuvel Pharmaceuticals Limited Nasdaq

Actions

CUVL

US1887691038

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:30:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
5,800 ^USD	+2,29 %		-2,68 %	-31,60 %

01/10	Clinuvel Pharmaceuticals Ltd présente à l’EADV de nouveaux cas de patients démontrant une réponse clinique à SCENESSE associé à une photothérapie par ultraviolets B à bande étroite chez des patients atteints de vitiligo	CI
09/09	Clinuvel Pharmaceuticals Ltd achève le développement de Zerokin, un dispositif d'administration à usage unique pour les formulations à libération contrôlée	CI

Communiqués

27/08	A decade of profitability provides foundation for CLINUVEL’s U.S. expansion	AQ
23/07	CLINUVEL implements strategic reorganisation to refocus on U.S. markets	AQ
20/07	CLINUVEL’s ADS to commence trading on Nasdaq	AQ
13/07	SCENESSE® approved for EPP in Canada	AQ
24/04	CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study	AQ
15/04	CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026	PU
26/03	Clinuvel Pharmaceuticals : global programs showcased at America’s largest dermatology conference	PU
27/02	Morgans rates CUV as Speculative Buy	AQ
12/01	Clinuvel Pharmaceuticals : Controlled-release injectable peptide platform evaluated in preclinical study	PU
12/11	Clinuvel Pharmaceuticals : Notice of change of interests of substantial holder	PU
17/10/25	Clinuvel Pharmaceuticals : Managing Director’s address	PU
29/09/25	CLINUVEL to advance novel pharmaceutical formulations in preclinical program	AQ
28/08/25	Clinuvel Pharmaceuticals : Annual Report 2025	PU
22/08/25	CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist	AQ
24/06/25	Clinuvel Pharmaceuticals : German Non-deal Roadshow Presentation	PU
07/05/25	CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105	AQ
04/03/25	Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025	AQ
27/02/25	Clinuvel Pharmaceuticals : First Half Results – FY2025	PU
06/12/24	Clinuvel Pharmaceuticals : Notice of initial substantial holder	PU
01/10/24	CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP	AQ
18/06/24	Afamelanotide in fair-skinned Parkinson’s patients	AQ
28/03/24	Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors	AQ
05/03/24	Malibu shines a light on CLINUVEL’s pioneering work in photomedicine	AQ
01/03/23	CLINUVEL Launches CYACÊLLE, Next Generation Solar Care	AQ
24/02/23	Global SCENESSE® demand drives increased CLINUVEL revenues, earnings	AQ